<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2019</study_start_year><data_sharing_plan>IPD Sharing (as of April 2019): No</data_sharing_plan><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2303689</full_dataset_link><location>Egypt</location><study_start_month>4</study_start_month><keyword>Mebendazole</keyword><keyword>Piperazine citrate</keyword><keyword>Piperazine</keyword><keyword>DMP 777</keyword><keyword>Bevacizumab</keyword><repository>ECRIN MDR</repository><study_status>Recruiting</study_status></additional><is_claimable>false</is_claimable><name>Mebendazole as Adjuvant Treatment for Colon Cancer</name><description>mebendazole treating colon cancer</description><dates><creation>2019-04-15</creation></dates><accession>2303689</accession><cross_references><ClinicalTrials___gov>NCT03925662</ClinicalTrials___gov></cross_references></HashMap>